NCT00704288Phase 2Completed
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
Study sponsor: Exelixis
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Primary completion2012-06Actual
Enrollment · participants222Actual
Source updated2024-02-05Last update listed in the registry record
Version history
Changes to this trial
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.